0001562180-22-006557.txt : 20220908 0001562180-22-006557.hdr.sgml : 20220908 20220908161641 ACCESSION NUMBER: 0001562180-22-006557 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220906 FILED AS OF DATE: 20220908 DATE AS OF CHANGE: 20220908 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MOORE JOHN R CENTRAL INDEX KEY: 0001191702 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40236 FILM NUMBER: 221234006 MAIL ADDRESS: STREET 1: 3200 WALNUT ST CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc. CENTRAL INDEX KEY: 0001710072 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821725586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3415 COLORADO AVE. CITY: BOULDER STATE: CO ZIP: 80303 BUSINESS PHONE: 303-735-8373 MAIL ADDRESS: STREET 1: 3415 COLORADO AVE. CITY: BOULDER STATE: CO ZIP: 80303 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2022-09-06 false 0001710072 Edgewise Therapeutics, Inc. EWTX 0001191702 MOORE JOHN R C/O EDGEWISE THERAPEUTICS, INC. 3145 COLORADO AVE BOULDER CO 80303 false true false false General Counsel Common Stock 2022-09-06 4 M false 4730.00 1.93 A 7730.00 D Common Stock 2022-09-06 4 S false 2379.00 10.8262 D 5351.00 D Common Stock 2022-09-06 4 S false 2351.00 10.992 D 3000.00 D Stock Option (Right to Buy) 1.93 2022-09-06 4 M false 4730.00 0.00 D 2030-12-15 Common Stock 4730.00 127727.00 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $9.93 to $10.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $10.93 to $11.08, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 1/48th of the shares subject to the option vest monthly beginning on January 16, 2021, subject to Reporting Person continuing as a service provider through each vest date. /s/ John R. Moore 2022-09-08